Pulmologix AB today announced the closing of a series B financing of EUR 9.6 million to develop a new Oral Non-Steroidal Anti-asthmatic (ONSA) for the treatment of early onset allergic asthma. The financing was led by Novo Seeds, the seed fund of Novo A/S, and Sunstone Capital of Denmark. Previous investors Forbion Capital Partners of the Netherlands and HealthCap participated in the round. “We are pleased to invest in Pulmologix and view this as an exciting opportunity in a common and undertreated disease” says Bobby Soni, Investment Director of Novo Seeds who together with Andreas Segerros of Sunstone now joins the Board of Directors.